七月 2026
- Home
- Prelude Therapeutics
七月 2026的Prelude Therapeutics市场份额分析
Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines. Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and […]
Prelude Therapeutics(包含公司地区分支机构)
查看更多网站流量和参与度信息- preludetx.com
Prelude Therapeutics收入截至 七月 2026为 25M - 50M
Prelude Therapeutics主要域名产生的收入
3 年中Prelude Therapeutics主要域名的收入
Prelude Therapeutics主要域名的收入
Prelude Therapeutics热门域名的总访问量
了解Prelude Therapeutics市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Prelude Therapeutics热门域名的平均访问时长
分析Prelude Therapeutics参与度指标。
过去 3 个月的平均访问时长
子公司明细
Prelude Therapeutics热门域名的平均页面浏览量
了解Prelude Therapeutics如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Prelude Therapeutics 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Prelude Therapeutics Incorporated attended event Annual Meeting on Jan 1st '26.Prelude Therapeutics presents preclinical data from development candidate, PRT13722, a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader at american association for cancer research (AACR) Annual Meeting 2026.
四月 20, 2026阅读更多
新闻Prelude Therapeutics Incorporated attends event 2025 AACR Annual Meeting.Prelude announces Presentations at 2025 AACR Annual Meeting.
四月 25, 2025阅读更多
新闻Prelude Therapeutics Incorporated attended event Barclays 27th Annual Global Healthcare Conference on Mar 5th '25.WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) - Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.
三月 5, 2025阅读更多
查看 Prelude Therapeutics 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
